Ma Chuan-Dong, Chen Can-Ming, Chen Xiao-Song, Liu Guang-Yu, Di Gen-Hong, Wu Jiong, Lu Jin-Song, Yang Wen-Tao, Chen Jia-Yi, Shao Zhi-Min, Shen Zhen-Zhou, Shen Kun-Wei
Department of Breast Surgery, Cancer Hospital, Fudan University, Shanghai, P.R. China.
Anticancer Res. 2008 Sep-Oct;28(5B):3093-7.
The purpose of this study was to evaluate retrospectively the efficacy and safety of neoadjuvant chemotherapy with vinorelbine-containing regimens in elderly patient with locally advanced breast cancer (LABC).
From 2002 to 2006, 14 female elderly patients with LABC underwent neoadjuvant chemotherapy with vinorelbine-containing regimens. Vinorelbine alone or in combination with pirarubicin/epirubicin was administered every 3 weeks (25 mg/m2, i.v., day 1 and day 8). All 14 patients received 2-6 cycles of chemotherapy.
The median age was 68.5 years (range 65 to 78 years). Six patients had stage IIIA breast tumor, 7 stage IIIB and 1 stage IIIC. There was 1 complete response and 10 partial responses, with an overall response rate of 78.57%, and stable disease in 3 patients (21.43%); there were no patients with progressive disease before surgery. After a median follow-up of 35 months, the estimated 3-year disease-free and overall survival rates were 57% and 69%, respectively.
The results of the current study showed that vinorelbine-containing neoadjuvant chemotherapy was effective and well-tolerated in elderly patients with LABC.
本研究的目的是回顾性评估含长春瑞滨方案的新辅助化疗在老年局部晚期乳腺癌（LABC）患者中的疗效和安全性。
2002年至2006年期间，14例老年女性LABC患者接受了含长春瑞滨方案的新辅助化疗。长春瑞滨单独使用或与吡柔比星/表柔比星联合使用，每3周给药一次（25mg/m²，静脉注射，第1天和第8天）。所有14例患者均接受了2 - 6周期的化疗。
中位年龄为68.5岁（范围65至78岁）。6例患者为IIIA期乳腺肿瘤，7例为IIIB期，1例为IIIC期。有1例完全缓解，10例部分缓解，总缓解率为78.57%，3例患者病情稳定（21.43%）；术前无疾病进展患者。中位随访35个月后，估计3年无病生存率和总生存率分别为57%和69%。
本研究结果表明，含长春瑞滨的新辅助化疗在老年LABC患者中有效且耐受性良好。
